Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PEXEVA vs Fluoxetine-Safety-Postpartum
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Paroxetine is a selective serotonin reuptake inhibitor (SSRI); it potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Posttraumatic stress disorder,Premenstrual dysphoric disorder,Vasomotor symptoms associated with menopause
Major depressive disorder,Obsessive-compulsive disorder,Bulimia nervosa,Panic disorder,Premenstrual dysphoric disorder (off-label),Bipolar depression (off-label),Social anxiety disorder (off-label)
Initial 10 mg orally once daily, increased gradually based on response and tolerability; maximum 50 mg once daily (paroxetine hydrochloride equivalent).
20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.
60-120 hours (chronic dosing); steady-state achieved in 4-5 weeks
Fluoxetine: 4-6 days (acute), 4-6 weeks (chronic); norfluoxetine: 4-16 days. Steady-state achieved after 2-4 weeks.
Extensively metabolized by CYP2D6; minor pathways include CYP3A4; undergoes oxidative and conjugation reactions.
Hepatic via CYP2D6, CYP2C9, CYP3A4; active metabolite norfluoxetine.
Primarily renal (70% as metabolites, 2% unchanged); fecal (27%)
Renal (80% as metabolites, 10% as unchanged drug) and fecal (15%)
98% bound to albumin and α1-acid glycoprotein
94% bound to albumin and alpha-1-acid glycoprotein
20-30 L/kg; large Vd indicates extensive tissue distribution
12-43 L/kg; extensive tissue distribution including brain, breast milk.
Oral: 50-80% (first-pass metabolism)
Oral: 95% (72% after first-pass); food may slightly decrease rate but not extent.
Creatinine clearance (Cr Cl) 30-59 m L/min: initially 10 mg once daily, maximum 40 mg once daily. Cr Cl < 30 m L/min or hemodialysis: initially 10 mg once daily, maximum 30 mg once daily.
No dose adjustment required for mild to moderate renal impairment (GFR ≥30 m L/min). For severe renal impairment (GFR <30 m L/min), use cautiously with a maximum dose of 40 mg/day.
Child-Pugh Class B or C: initially 10 mg once daily, maximum 30 mg once daily. Child-Pugh Class A: no adjustment recommended.
Child-Pugh Class A: 20 mg every other day; Class B: 20 mg every third day; Class C: avoid use or use 10 mg every third day with careful monitoring.
Not FDA-approved for patients < 18 years; use not recommended due to increased risk of suicidal thoughts and behaviors.
Children (8-12 years): 10-20 mg orally once daily; adolescents (13-17 years): 20 mg orally once daily. Maximum 60 mg/day. Weight-based: 0.5-1.0 mg/kg/day, titrate to maximum 1.5 mg/kg/day.
Initial dose 10 mg orally once daily; maximum 40 mg once daily. Elderly patients may have increased plasma concentrations and require slower titration.
Initial dose 10 mg orally once daily; titrate slowly to a maximum of 40 mg/day due to increased half-life and risk of hyponatremia and QT prolongation.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality in children, adolescents, and young adults,Serotonin syndrome,Discontinuation syndrome (withdrawal),Activation of mania/hypomania,Seizures,Angle-closure glaucoma,Increased intraocular pressure,Hyponatremia,Abnormal bleeding,Sexual dysfunction,Bone fracture risk,Drug interactions with MAOIs and other serotonergic drugs
Serotonin syndrome; risk of bleeding; activation of mania/hypomania; hyponatremia; discontinuation syndrome; QT prolongation (overdose).
Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI,Concurrent use with tryptophan,Concurrent use with pimozide,Known hypersensitivity to paroxetine or any excipient
Concurrent use with MAOIs (or within 14 days); concurrent use with thioridazine or pimozide; known hypersensitivity to fluoxetine.
Avoid grapefruit and grapefruit juice, as they can increase paroxetine levels and risk of toxicity. Alcohol may exacerbate CNS depression and should be limited. No other significant food interactions.
No specific food interactions; avoid grapefruit juice as it may increase fluoxetine levels. Take with or without food; if GI upset occurs, take with food.
PEXEVA (paroxetine) is classified as FDA Pregnancy Category D. First trimester exposure is associated with a 1.5- to 2-fold increased risk of congenital cardiac malformations, particularly ventricular septal defects, and an increased risk of omphalocele and craniosynostosis. Third trimester exposure may result in neonatal adaptation syndrome (e.g., respiratory distress, jitteriness, poor feeding, persistent crying) and rare cases of persistent pulmonary hypertension of the newborn (PPHN). The risk is dose-dependent and highest with doses above 25 mg/day.
First trimester: Exposure associated with a small increased risk of cardiovascular malformations, primarily ventricular septal defects (absolute risk ~2-3% vs 1% baseline). Second/third trimester: Persistent pulmonary hypertension of the newborn (PPHN) risk ~1.5-2 times baseline; risk of preterm birth and low birth weight. Late third trimester: Risk of poor neonatal adaptation syndrome (PNAS) including jitteriness, respiratory distress, feeding difficulties, and irritability.
Paroxetine is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.5-0.7. Though relative infant doses are low (typically <2% of maternal weight-adjusted dose), adverse effects such as irritability, poor feeding, and drowsiness have been reported. Caution is advised, particularly with high maternal doses; non-pharmacologic strategies or alternative antidepressants with more favorable lactation profiles may be preferred.
Fluoxetine and its active metabolite norfluoxetine are excreted into breast milk; M/P ratio ~0.3-1.0 for fluoxetine and ~0.5-2.0 for norfluoxetine. Relative infant dose approximately 2-12% of maternal weight-adjusted dose. Cases of colic, irritability, and poor feeding in breastfed infants have been reported. Generally considered compatible with breastfeeding; however, monitor infant for sedation, poor weight gain, and development.
Pregnancy can alter paroxetine pharmacokinetics, leading to increased clearance and reduced plasma concentrations, particularly in the second and third trimesters. Dose adjustments (e.g., up to 1.5-2 times the pre-pregnancy dose) may be required to maintain therapeutic efficacy. However, higher doses increase fetal risk, so lowest effective dose should be used. Tapering or switching to a safer agent (e.g., fluoxetine or sertraline) is often considered. Postpartum, doses should be gradually reduced to pre-pregnancy levels to avoid toxicity.
Pregnancy increases fluoxetine clearance and decreases plasma concentrations, especially in the third trimester. Dose may need to be increased by 20-50% (e.g., from 20 mg to 30-40 mg daily) to maintain therapeutic effect. Consider therapeutic drug monitoring if available. Postpartum, dose should be reduced to pre-pregnancy levels within 48-72 hours due to reversal of pharmacokinetic changes.
Pexeva (paroxetine mesylate) is an SSRI antidepressant. Due to its short half-life, abrupt discontinuation may cause withdrawal syndrome. It is also indicated for panic disorder, OCD, and social anxiety disorder. Use with caution in patients with narrow-angle glaucoma, as it can precipitate acute angle closure. Monitor for hyponatremia in elderly patients. Avoid concurrent use with MAOIs or other serotonergic agents due to risk of serotonin syndrome.
Fluoxetine has a long half-life (4-6 days, norfluoxetine 4-16 days) resulting in steady-state after 2-4 weeks; use lower starting doses (10 mg daily) in postpartum women to minimize side effects; monitor for neonatal adaptation syndrome if used in third trimester; consider dose adjustment in hepatic impairment; avoid in breastfeeding unless benefit outweighs risk due to presence in breast milk.
Take exactly as prescribed; do not stop suddenly. If you miss a dose, take it as soon as you remember unless it is close to the next dose. Do not double doses.,May take up to 4 weeks to feel full benefit. Continue medication even if you feel better.,Avoid alcohol and grapefruit juice. Grapefruit can increase Pexeva levels and side effects.,May cause drowsiness, dizziness, or blurred vision. Do not drive or operate machinery until you know how Pexeva affects you.,Report any suicidal thoughts, agitation, or worsening depression immediately to your doctor.,Common side effects include nausea, dry mouth, constipation, decreased appetite, and sexual dysfunction. These often improve over time.
Take fluoxetine exactly as prescribed, typically once daily in the morning.,It may take 4 weeks or longer to feel full benefit; do not stop abruptly.,Common side effects include nausea, headache, insomnia, and sexual dysfunction.,Contact your doctor if you experience rash, unusual bleeding, or suicidal thoughts.,Avoid alcohol while taking this medication.,Do not breastfeed without discussing risks with your healthcare provider.
No interactions on record
"Pazopanib, a tyrosine kinase inhibitor, inhibits CYP2D6 activity, leading to reduced metabolism of fluoxetine, a substrate of CYP2D6. This results in increased serum concentrations of fluoxetine and its active metabolite norfluoxetine, elevating the risk of serotonin-related adverse effects such as serotonin syndrome, nausea, and insomnia. The interaction is clinically significant and may require dose adjustment of fluoxetine."
"Concurrent administration of etomidate and fluoxetine may potentiate the anesthetic and sedative effects, as fluoxetine inhibits CYP3A4 which is involved in the metabolism of etomidate, leading to increased etomidate plasma concentrations and prolonged recovery time. Additionally, both drugs can cause QTc interval prolongation, increasing the risk of torsades de pointes and other ventricular arrhythmias. Patients may experience enhanced central nervous system depression, respiratory depression, and hypotension."
"Concomitant use of tolcapone, a catechol-O-methyltransferase (COMT) inhibitor used in Parkinson's disease, with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), may potentiate serotonergic effects leading to serotonin syndrome, characterized by autonomic instability, neuromuscular hyperactivity, and altered mental status. Additionally, both drugs undergo hepatic metabolism via CYP450 enzymes, and fluoxetine's inhibition of CYP2C9 and CYP3A4 may reduce tolcapone clearance, increasing the risk of hepatotoxicity and other adverse effects. The combination requires careful monitoring for signs of serotonin toxicity and liver injury."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PEXEVA vs Fluoxetine-Safety-Postpartum, answered by our medical review team.
PEXEVA is a SSRI Antidepressant that works by Paroxetine is a selective serotonin reuptake inhibitor (SSRI); it potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.. Fluoxetine-Safety-Postpartum is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake in the synaptic cleft, potentiating serotonergic activity in the CNS.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PEXEVA and Fluoxetine-Safety-Postpartum depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PEXEVA is: Initial 10 mg orally once daily, increased gradually based on response and tolerability; maximum 50 mg once daily (paroxetine hydrochloride equivalent).. The standard adult dose of Fluoxetine-Safety-Postpartum is: 20 mg orally once daily, initially; may increase after several weeks to a maximum of 80 mg/day. Administer in the morning.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PEXEVA and Fluoxetine-Safety-Postpartum in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PEXEVA is classified as Category C. PEXEVA (paroxetine) is classified as FDA Pregnancy Category D. First trimester exposure is associated with a 1.5- to 2-fold increased risk of congenital cardiac malformations, part. Fluoxetine-Safety-Postpartum is classified as Category A/B. First trimester: Exposure associated with a small increased risk of cardiovascular malformations, primarily ventricular septal defects (absolute risk ~2-3% vs 1% baseline). Second/. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.